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Bacteria can resist antibiotics by sequestering them
Antibiotics have underpinned numerous advances including surgery, organ transplantation,
and cancer chemotherapy. Therefore, the emergence of bacterial pathogens that are resistant
to therapeutic antibiotics poses enormous challenges to modern medicine [1].
One of the key mechanisms by which bacteria resist antibiotics is the production of
enzymes that inactivate antibacterial molecules via hydrolysis or chemical modification [1].
However, there is growing evidence that bacteria can also survive exposure to antibiotics by
releasing molecules into the extracellular space that sequester the drug and prevent it from
reaching its target. Some of these ‘antibiotic interceptors’ function as decoys by mimicking tar-
get molecules, whilst others share no obvious similarity to the target at all (Fig 1). Many inter-
ceptors also function as structural components of biofilms, thereby contributing to the
antibiotic tolerance of these bacterial communities.
This article summarises our current understanding of antibiotic interceptors, explores the
selection pressures for the emergence of these systems, and identifies future research avenues
to characterise and overcome antimicrobial interception strategies.
Membrane lipid decoys
Daptomycin and colistin are considered antibiotics of last resort, used to treat infections
caused by highly drug-resistant gram-positive and gram-negative bacteria, respectively. They
are both peptide antibiotics with functional similarity to cationic antimicrobial peptides
(AMPs) found in the host. Daptomycin targets phosphatidylglycerol in the membrane of
gram-positive bacteria, resulting in membrane depolarisation and bacterial death, whilst colis-
tin binds to lipopolysaccharide (LPS) on the surface of gram-negative bacteria and disrupts
membrane function [2,3].
Recent work has shown that gram-positive bacteria, including Staphylococcus aureus and
Enterococcus faecalis, can evade daptomycin by releasing phosphatidylglycerol decoys from the
membrane in response to the antibiotic [4,5]. These decoys sequester daptomycin, preventing
the antibiotic from inserting into the bacterial membrane, and exist as monomers, indicating
that their concentration does not exceed the critical micelle concentration [6]. The release of
phospholipids occurs via a process that requires de novo lipid biosynthesis, demonstrating
that this constitutes an active defence mechanism rather than simply arising as the result of
damage to the membrane caused by the antibiotic [4,5]. However, neither the mechanism by
which bacteria detect daptomycin nor the process by which monomeric phospholipids are
released are understood.
Gram-negative bacteria also appear to employ decoys to survive exposure to membrane-
targeting antimicrobials. Although the release of outer-membrane vesicles (OMVs) from







Citation: Sabnis A, Ledger EVK, Pader V, Edwards
AM (2018) Antibiotic interceptors: Creating safe
spaces for bacteria. PLoS Pathog 14(4): e1006924.
https://doi.org/10.1371/journal.ppat.1006924
Editor: Kimberly A. Kline, Nanyang Technological
University, SINGAPORE
Published: April 19, 2018
Copyright: © 2018 Sabnis et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: EVKL is supported by a Wellcome Trust
PhD Studentship (203812/Z/16/Z). AS is supported
by a Medical Research Council PhD Studentship
(MR/N014103/1). AME acknowledges funding
from the Department of Medicine, Imperial College
and from the Imperial NIHR Biomedical Research
Centre, Imperial College London. The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
gram-negative bacteria, such as Escherichia coli and Pseudomonas aeruginosa, occurs in the
absence of antibiotic stress, the rate of vesicle production increases significantly in response to
colistin or polymyxin B [7]. The released OMVs act as decoy receptors for these antibacterial
agents, enabling bacteria to survive otherwise lethal concentrations of the antibiotics [7,8]. It is
unknown whether the release of OMVs in response to membrane-targeting antibacterials is a
regulated process or simply a consequence of membrane disruption. However, since OMV
release can be regulated independently of membrane disruption, it is feasible that vesicle
release in response to polymyxins forms part of a dedicated defence mechanism against these
antibiotics [9].
Antimicrobial interception by proteins
Burkholderia cenocepacia is a major cause of opportunistic lung infections, particularly in
patients with cystic fibrosis, and is inherently resistant to many antibiotics. Upon exposure to
bactericidal antibiotics, including polymyxin B, rifampicin, norfloxacin, and ceftazidime, B.
cenocepacia releases a small protein known as a lipocalin, which sequesters the inducing antibi-
otic [10]. Once bound to the lipocalin, the antibiotic is unable to engage its target, enabling the
bacterium to grow in the presence of otherwise inhibitory concentrations of the drugs [10].
The presence of lipocalin genes in several other pathogens, including Mycobacterium tubercu-
losis and S. aureus, raises the possibility that this constitutes a broadly conserved mechanism of
antibiotic interception [10].
An additional mechanism by which proteins can become interceptors is via their release in
OMVs. For example, proteases within OMVs were found to inactivate the AMP melittin [8].
Fig 1. Bacteria release a diverse array of molecules to intercept antibiotics. AMP, antimicrobial peptide; HNP-1, human neutrophil protein-1; HβD-3,
human β-defensin 3.
https://doi.org/10.1371/journal.ppat.1006924.g001
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Similarly, the presence of β-lactamases in membrane vesicles released from Moraxella catar-
rhalis or S. aureus protects both the producer and drug-sensitive bystander bacteria from β-lac-
tams by hydrolysing the antibiotic [11,12].
Antimicrobial interception by polysaccharides
Many pathogenic bacteria are enclosed within a polysaccharide capsule, which protects the cell
from host immune defences, including phagocytosis, complement peptides and AMPs such as
human neutrophil protein-1 (HNP-1), or the cathelicidin LL-37 [13,14]. However, exposure of
Klebsiella pneumoniae, Streptococcus pneumoniae, or P. aeruginosa to the peptide antibiotic
polymyxin B or HNP-1 triggers the release of polysaccharide from the bacterial surface [15]. It
is unknown whether capsule release is due to damage caused by the antimicrobials or a specific
bacterial response to stress, but this phenomenon promotes bacterial survival by sequestering
polymyxin B and HNP-1 [15]. Furthermore, exposure of the opportunistic pathogen Acineto-
bacter baumanii to chloramphenicol or erythromycin results in hyperproduction of capsular
exopolysaccharide, which confers resistance to these antibiotics, although the regulation and
mechanism of this process is unclear [16].
In addition to capsular polysaccharide, other polysaccharides frequently provide an impor-
tant structural component of biofilms, where they can also modulate susceptibility to antimi-
crobials. For example, the Psl exopolysaccharide contributes to the tolerance of P. aeruginosa
biofilms to colistin and tobramycin, most likely by sequestering the antibiotics, as observed for
capsular polysaccharides [17].
Antimicrobial sequestration by DNA
Like exopolysaccharides, extracellular DNA (eDNA) is a major structural component of bio-
films, as well as sequestering positively charged antimicrobials via electrostatic interactions
[18]. For example, P. aeruginosa biofilms rich in eDNA can sequester aminoglycosides such as
tobramycin, leading to increased bacterial survival [19]. Similarly, Staphylococcus epidermidis
biofilms exposed to subinhibitory concentrations of vancomycin contain higher levels of
eDNA than unexposed biofilms, although the regulatory and mechanistic basis for this is
unknown [20]. This eDNA binds vancomycin, impeding its penetration through the biofilm,
leading to increased bacterial survival [20]. In addition to antibiotics, eDNA also binds human
β-defensin 3, a cationic host defence AMP, reducing its ability to kill both planktonic and bio-
film forms of Haemophilus influenzae [21].
What has driven the evolution of antibiotic interceptors?
Many bacteria exist in single or polymicrobial biofilms that are maintained by extracellular
polymeric substances such as DNA, polysaccharides, proteins, and lipids [18]. Therefore, the
evolution of biofilm formation may have provided the mechanisms used in interceptor pro-
duction and release. Subsequently, it is likely that intermicrobial competition selected for the
use of extracellular products as antibiotic interceptors. Whilst antibiotic resistance is a recent
clinical problem, the underlying mechanisms are ancient, reflecting the presence of antibiotic-
producing fungi and bacteria in the environment [22]. Bacteriophages are also prevalent in the
environment and may, therefore, have contributed the emergence of OMVs as an extracellular
defence mechanism [7].
In the context of polymicrobial biofilms, antibiotic interceptors become ‘public goods’, a
shared resource between the bacteria that produce them and other cells that do not. This
shared-goods approach may reduce the overall cost of producing interceptors whilst maintain-
ing a high level of protection [17].
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In addition to the threats from antibiotic-producing competitors and bacteriophages, path-
ogens must also overcome host defences. Since many of the interceptors described above pro-
tect bacteria from AMPs as well as antibiotics, the host immune system may have provided
further selection pressure for the evolution of antibiotic interceptors [4,7,8,13,14,21,23]. There-
fore, antibiotic interceptors may have evolved to provide bacteria with an innate defence
against the broad spectrum of threats posed by competitors, bacteriophages, and host
defences.
Summary and future directions
The frequent inability of apparently appropriate antibiotic therapy to clear bacterial infections
suggests that mechanisms beyond dedicated antibiotic resistance modulate treatment out-
comes. One such mechanism involves the release of molecules into the extracellular space that
sequester antibiotics before they can engage with their target. These recently discovered pro-
cesses underscore the diversity of mechanisms by which pathogens have evolved resistance to
both host defences and antibiotics (Fig 1, Table 1). However, whilst we are beginning to iden-
tify and characterise antibiotic interceptors, several major questions remain (Table 2). In par-
ticular, our lack of understanding of these mechanisms has made it difficult to fully assess their
contribution to treatment failure. For example, the lack of mutants defective for capsule release
Table 1. Summary of antibiotic interceptors.
Class of
Interceptor
Mechanism of Interception Bacterial Species Antimicrobials Sequestered Reference





Release of OMVs E. coli Polymyxin B, colistin [6],[7]
Transport of hydrolytic enzymes within OMVs E. coli Melittin [8],[9]
M. catarrhalis Amoxicillin [11]Protein
Release of lipocalins B. cenocepacia Rifampicin, norfloxacin, ceftazidime, polymyxin
B
[10]





HNP-1, polymyxin B [13–17]
DNA Release of eDNA in biofilms P. aeruginosa Tobramycin, gentamicin [19]
S. epidermidis Vancomycin [20]
H. influenzae Human beta-defensin-3 [21]
Abbreviations: eDNA, extracellular DNA; HNP-1, human neutrophil protein-1; OMVs, outer membrane vesicles.
https://doi.org/10.1371/journal.ppat.1006924.t001
Table 2. Outstanding questions.
Outstanding Questions:
1. What is the contribution of antibiotic interceptors to clinical treatment failure?
2. How do bacteria sense the presence of antibiotics and AMPs?
3. How do bacteria release interceptors?
4. Can we block the production of interceptors to promote treatment outcomes?
Abbreviation: AMP, antimicrobial peptide.
https://doi.org/10.1371/journal.ppat.1006924.t002
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or OMV production prevents appropriate testing of antibiotic susceptibility in vivo. Chal-
lenges in studying interceptors may be resolved using small-molecule inhibitors. For example,
it has been shown that daptomycin-induced phospholipid release can be partially inhibited
by the β-lactam antibiotic oxacillin [4]. In addition to determining the contribution of antibi-
otic interception to treatment failure, this approach may also improve treatment outcomes by
identifying adjunctive therapeutic approaches that block the production of antimicrobial-
sequestering molecules. Such an approach may also disrupt biofilm formation since many
interceptors are important components of these structures [18]. In addition, since interceptors
do not chemically inactivate antimicrobials, it may be possible to develop adjunctive therapeu-
tic strategies that prevent or reverse antibiotic sequestration. For example, lipocalins could not
sequester antibiotics when fat-soluble vitamins were present [10]. Finally, since several antibi-
otic interceptors also confer resistance to AMPs, inhibitors of interceptor production or func-
tion may contribute to treatment success by increasing the susceptibility of pathogens to host
defences.
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